Clinical Trials
- A Multicentre French Prospective Study of Children With Food Protein Induced Enterocolitis Syndrome in Its Acute Form
- Longitudinal Study of the Intestinal, Cutaneous and Salivary Microbiota in Children With Food-induced Enterocolitis Syndrome (SEIPA)
- Novel Blood Test to Predict Safe Foods for Infants and Toddlers With Food Protein-induced Enterocolitis Syndrome (FPIES)
- Quality of Life and Eating Disorders in Children With FPIES, Food Allergy or Celiac Disease
- A Comparison of Visual Functions and Side-effects After DSAEK or DMEK for Fuchs’ Endothelial Dystrophy
- A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD)
- A Phase 1/ Phase 2 Study of TTHX1114(NM141)
- Air Versus SF6 for Descemet’s Membrane Endothelial Keratoplasty (DMEK)
- Analysis of the Genotype/Phenotype Relationship in the Fuchs’ Corneal Endothelial Dystrophy in France.
- Assessment of Corneal Endothelial Function Following Hypoxic Stress
- Assessment of Corneal Graft Attachment in Patients With Fuchs Endothelial Corneal Dystrophy Following DMEK Using Ultra-high Resolution OCT
- Comparing Endoglide to Endoserter for DSAEK Graft Insertion
- Comparison of Corneal Grafts Cultured in Serum-free Versus Corneal Grafts Cultured in Serum Supplemented Culture Media
- Comparison of Two Techniques in Achieving Corneal Graft
- Descemet Endothelial Thickness Comparison Trial II
- DISCOVER Study: Microscope-integrated Intraoperative OCT Study
- DMEK Versus DSAEK Study
- DSAEK- Postoperative Positioning and Transplant Dislocation
- Evaluation of Amphotericin B in Optisol-GS for Prevention of Post-Keratoplasty Fungal Infections.
- Evaluation of the Efficacy of Descemet Membrane Transplantation for the Treatment of Fuchs’ Endothelial Dystrophy
- Eye Drops for Early Morning-Associated Corneal Swelling of the Cornea
- Fuchs’ Endothelial Dystrophy: Clinical Characteristics, Treatment Outcome, and Pathology
- Fuchs’ Torsional Phaco Study
- Glanatec(R) for Descemet Stripping in Fuch’s Endothelial Dystrophy
- Impact of Donor Diabetes on DMEK Success and Endothelial Cell Loss
- Netarsudil Use After Descemetorhexis Without Endothelial Keratoplasty
- Netarsudil Use After Descemtorhexis Without Endothelial Keratoplasty
- OCT-guided DSAEK Graft Shaping and Smoothing
- ODM 5 in the Treatment of Corneal Edematous Fuchs’ Endothelial Dystrophy
- Outcome After Descemet Membrane Endothelial Keratoplasty (DMEK) and Ultra-thin Descemet Stripping Automated Endothelial Keratoplasty (DSAEK)
- Phase 1 Study to Evaluate the Safety and Tolerability of EO1404 in the Treatment of Corneal Edema
- PIONEER: Intraoperative and Perioperative OCT Study
- Predictive Factors of Good Results After Primary Descemet’s Membrane Endothelial Keratoplasty (DMEK)
- Predictive Factors of Graft Detachment Following Dmek
- Rhopressa for Corneal Edema Associated With Fuchs Dystrophy
- Ripasudil 0.4% Eye Drops in Fuchs Endothelial Corneal Dystrophy
- Ripasudil for Enhanced Corneal Clearing Following Descemet Membrane Endothelial Keratoplasty in Fuchs’ Dystrophy
- Risk Assessment for Progression to DMEK Following Cataract Surgery in Fuchs Endothelial Corneal Dystrophy
- Safety and Efficacy of Tissue Engineered Endothelial Keratoplasty
- Study of Endothelial Keratoplasty Outcomes
- Study of Eye Bank Pre-cut Donor Grafts for Endothelial Keratoplasty
- Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema
- Study of the Effect of Aspheric Lenses in Patients With Fuch’s Dystrophy
- Study to Assess Safety and Tolerability of Multiple Doses of EO2002
- Study to Investigate the Safety and Efficacy of K-321 in Patients With Fuchs Endothelial Corneal Dystrophy (FECD) Following Descemetorhexis
- Study With QR-504a to Evaluate Safety, Tolerability & Corneal Endothelium Molecular Biomarker(s) in Subjects With FECD3
- Supine Positioning for Graft Attachment After Descemet Membrane Endothelial Keratoplasty
- Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch’s Endothelial Corneal Dystrophy
- Technique And Results In Endothelial Keratoplasty
- The ADVISE Study: Advanced Visualization In Corneal Surgery Evaluation
- The BELGIAN ENDOTHELIAL SURGICAL TRANSPLANT of the CORNEA
- The Molecular Pathogenesis of Late-onset Fuchs’ Endothelial Corneal Dystrophy
- The OPTIMISE Study
- The Postoperative Head Position as a Predictor of the Surgical Outcome After DMEK
- Trial of Netarsudil for Acceleration of Corneal Endothelial Restoration
- Trial of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation
- TTHX1114(NM141) in Combination With DWEK/DSO
- Using the Optovue OCT to Select IOL Power
- A Feasibility Phase II Study in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers
- A Prospective Study of UCAD for Diagnosing Benign or Malignant Biliary Obstruction and Follow-up
- A Randomized, Open, Prospective Clinical Research of Fluorouracil Implant to Improve Surgical Gallbladder Cancer and Bile Duct Cancer
- A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection
- A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With Advanced Biliary Tract Cancer
- A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers
- ABC-08: Phase Ib Trial of Acelarin in Combination With Cisplatin in Locally Advanced/ Metastatic Biliary Tract Cancers
- Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers
- Adjuvant Chemoradiation for Patients With High-risk reseCtable Extrahepatic chOlangiocaRcinoma and gallblaDder Cancer
- Adjuvant Palliative Capecitabine and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Biliary Tract Cancer
- Alcohol Consumption and Gallbladder Cancer
- Anonymous Testing of Pathology Specimens for BRCA Mutations in Ashkenazi Jewish Individuals Who Have Cancer
- Behavioral Weight Loss Program for Cancer Survivors in Maryland
- Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors
- Biliary Metal Stent Study: Metal Stents for Management of Distal Malignant Biliary Obstruction
- Biliary Stenting With or Without Photodynamic Therapy in Treating Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors That Cannot Be Removed by Surgery
- BMS-247550 in Treating Patients With Liver or Gallbladder Cancer
- Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder
- Capecitabine or Observation After Surgery in Treating Patients With Biliary Tract Cancer
- Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer
- Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers
- Chemothetapy FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
- Chile Biliary Longitudinal Study
- Combination Chemotherapy in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer
- Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer
- Comparing the Current Hydration Regimen for the ABC02 Chemotherapy Regimen Versus a Shorter Hydration
- Comparison Between Unilateral Versus Bilateral Stenting for Malignant Hilar Biliary Obstruction to Use a LCD Stent
- Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms
- Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
- Dasatinib in Preventing Oxaliplatin-Induced Peripheral Neuropathy in Patients With Colorectal Cancer Receiving FOLFOX and Bevacizumab
- Deep Learning Radiogenomics For Individualized Therapy in Unresectable Gallbladder Cancer
- Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer
- DX-8951f in Treating Patients With Biliary Cancer
- Endoscopic Versus Percutaneous Drainage For Hilar Block in Gall Bladder Cancer
- Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer
- Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer
- Feasibility Study to Investigate Rectal Mucus in Aero-Digestive Tract Cancer.
- Fluorouracil, Cisplatin, and Radiation Therapy or Gemcitabine and Oxaliplatin in Treating Patients With Nonmetastatic Biliary Tract Cancer That Cannot Be Removed By Surgery
- Gemcitabine and Capecitabine in Treating Patients With Advanced and/or Inoperable Cholangiocarcinoma or Carcinoma of the Gallbladder
- Gemcitabine and Cisplatin for Gallbladder and Biliary Tract Cancer
- Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy
- Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery
- Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L Biliary Tract Cancer (BTC)
- Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer
- Gemcitabine With or Without Cisplatin in Treating Patients With Unresectable Locally Advanced or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors
- Gemcitabine With/Out Capecitabine in Locally Advanced, Unresectable, or Metastatic Biliary Cancer
- Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer
- Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers
- Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
- Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies
- HAI Via Interventionally Implanted Port Catheter Systems
- Hepatobiliary Tumors Tissue Samples Acquisition
- Identification of New Biomarkers for Patients With Cholangiocarcinoma and Gallbladder Cancer
- Initial Study of Gallbladder Cancer in Chile
- Irinotecan in Treating Patients With Advanced Gallbladder or Bile Duct Cancer
- Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer
- Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery
- Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer
- M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)
- MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery
- Molecularly Target Therapy With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
- Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
- Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer
- NGS in Gallbladder Cancer and Response to Treatment
- Observational Study on Patients With Hepatobiliary Tumors.
- Oxaliplatin, Gemcitabine, Erlotinib, and Radiation Therapy in Treating Patients With Unresectable and/or Metastatic Pancreatic Cancer or Biliary Tract Cancer
- Palliative Biliary Stenting on the Quality of Life of Patients With Unresectable Carcinoma Gallbladder With Hiliar Block.
- Pembrolizumab in Biliary Tract Cancer
- Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)
- Perioperative Therapy Preoperative Chemotherapy Versus Chemoradiotherapy in Locally Advanced Gall Bladder Cancers
- Photodynamic Therapy in Treating Patients With Cancer of the Bile Duct, Gallbladder, or Pancreas
- PLATON – Platform for Analyzing Targetable Tumor Mutations (Pilot-study)
- Quality Of Life in Patients With Malignant Biliary Obstruction
- Radiation Stent Versus Self-expanding Metallic Stents (SEMS) for Palliative Treatment of Malignant Biliary Stricture
- Radiation Therapy in Treating Patients With Bile Duct, Gallbladder, or Pancreatic Cancer
- Rebeccamycin Analogue in Treating Patients With Advanced Liver and/or Biliary Cancer
- Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
- S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma
- S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma
- S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
- Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery
- Stent Placement With or Without Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Treating Patients With Stage III or Stage IV Cholangiocarcinoma That Cannot Be Removed By Surgery
- Storage of Bile From Routine Procedures to Study Risk Factors
- Study of Gemcitabine and Carboplatin in the Treatment of Metastatic or Recurrent Cholangiocarcinoma/Gallbladder Cancer
- Study of People With Metastatic Gastrointestinal Epithelial Cancer Administering Tumor-Infiltrating Lymphocytes in Which the Gene Encoding CISH Was Inactivated Using the CRISPR/Cas9 System
- Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
- Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer
- Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor
- The Effect in Wedge Resection and IVb/V Resection of the Liver for Gallbladder Cancer
- The PLATON Network
- The Relationship Between Triceps Skinfold and Overall Survival of Pancreas, Bile Duct, Gallbladder Cancer
- Three Dimension Laparoscopic Versus Open Surgery for Gallbladder Carcinoma
- Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery
- Triapine and Gemcitabine Hydrochloride in Gallbladder Cancer
- Two-in-one Covered and Uncovered Metal Stent
- [68 Ga]-DOTANOC PET/CT in GEP-NETs
- 177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs
- A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors
- A Phase 1 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of PT217 in Patients With Advanced Refractory Cancers Expressing DLL3
- A Study of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3
- A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor
- A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET
- Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors
- Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)
- Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients
- Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors
- FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas
- Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs
- Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
- Neuroendocrine Tumors – Patient Reported Outcomes
- Nutrition in Gastroenteropancreatic Neuroendocrine Tumor
- Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.
- Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
- Quality of Life, Treatment Experience and Cost of Treatment With Somatostatin Analogues in Patients With Gastroenteropancreatic Neuroendocrine Tumours
- Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETs
- Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors
- Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs
- Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
- TEP With 68-DOTANOC in Gastroenteropancreatic Neuroendocrine Tumors
- The Lyon Real World Evidence in Metastatic NeuroEndocrine Tumours
- The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases
- TQ (Thymoquione) Formula With Nivolumab and Ipilimumab in Gastroenteropancreatic Neuroendocrine Carcinomas
- (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors
- (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
- (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
- 5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk
- 68Ga-NOTA-RM26 PET/CT for the Detection of Gastrointestinal Stromal Tumor
- A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST
- A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I)
- A Clinical Trial With a New Needle Device Comparing Two Needles for EUS_FNA of Solid Lesions.
- A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
- A Drug-drug Interaction Study of Avapritinib and Midazolam
- A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients With Advanced GIST
- A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
- A Multicenter Study of Avapritinib Efficacy and Safety of Metastatic or Unresectable Gastrointestinal Stromal Tumors
- A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib
- A Phase 3 Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib
- A Phase I/II Study of Sunitinib Malate (SU011248) In Patients With Gastrointestinal Stromal Tumor (GIST)
- A Prospective, Multicenter Study on Best Clinical Use of Imatinib in the Advanced Gastrointestinal Stromal Tumors
- A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments
- A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)
- A Real-world Comparison of FNB and FNA in ICH-required Lesions.
- A Retrospective Clinical Records Review of Patients Diagnosed With Gastrointestinal Stromal Tumour at Two Tertiary Institutes in Singapore
- A Retrospective Pharmacokinetics and Pharmacogenomics Research of Imatinib in Gastrointestinal Stromal Tumor Treatment
- A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)
- A Study of AUY922 for GIST(Gastrointestinal Stromal Tumor) Patients
- A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy
- A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors
- A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor
- A Study of DCC-2618 (Ripretinib) Evaluating Efficacy, Safety, and Pharmacokinetics In Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
- A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib
- A Study of Famitinib in Patients With Gastrointestinal Stromal Tumor
- A Study of HQP1351 in Patients With GIST or Other Solid Tumors
- A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs
- A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
- A Study of Nilotinib Versus Imatinib in GIST Patients
- A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors
- A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)
- A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
- A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
- A Study to Assess the Efficacy and Safety of DCC-2618 and Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumors After Treatment With Imatinib
- A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST)
- A Study to Evaluate the Safety of Intuvax Administered Intra-tumorally in Patients With Gastrointestinal Stromal Tumors
- A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST
- Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation
- Advanced Gastrointestinal Endoscopic Imaging
- An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST)
- Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST
- Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA
- BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
- Caphosol in Oral Mucositis Due to Targeted Therapy
- CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor
- Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on Imatinib
- Circulating Cell-free Tumor DNA in the Plasma of Patients With Gastrointestinal Stromal Tumors (GIST)
- Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- Clinical Evaluation of Genetron D842V PCR Kit in GIST Patients
- Clinical Outcome of Female Non-gastric Gastrointestinal Stromal Tumor
- Collection of Biospecimen & Clinical Information in Patients w/ Gastrointestinal Cancers
- Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed Conditions
- Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
- Continuation of Drug Supply in Chinese Patients After CAMN107DBR01study Termination
- ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST
- Current Management of Gastrointestinal Stromal Tumors (GIST) in the Region of Coquimbo
- Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients
- Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic
- Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors
- Detection of CF-DNA in Patients With Gastrointestinal Stromal Tumors (GIST)
- Distress, Medication Adherence and Care Needs in Patients With CML and GIST Receiving Oral Targeted Therapy
- DNX-2440 for Resectable Colorectal Liver Metastasis
- Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258
- Dovitinib in Combination With Imatinib in Patients With Gastrointestinal Stromal Tumors
- Doxorubicin Hydrochloride and Alvocidib in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery
- DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumor (GIST)
- Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic GIST
- Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib
- Efficacy and Safety of Anlotinib in Patients With Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib: a Prospective, Single Arm and Multicenter Trial
- Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib
- Efficacy and Safety of Famitini Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib
- Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib
- Efficacy of Imatinib in Patients With Intermediate-risk Gastrointestinal Stromal Tumor With a High-risk Genomic Grade Index
- Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.
- Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST)
- Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)
- Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)
- Endoscopic Full Thickness Resection of Gastric Subepithelial Tumors (FROST)
- Entacapone Combination With Imatinib for Treatment of GIST
- Epacadostat and Pembrolizumab in Patients With GIST
- ESTD vs. VATS for Upper Gastrointestinal Submucosal Tumors
- EUS-Elastography and Contrast-Enhanced EUS Diagnostic Accuracy in the Differential Diagnosis of Subepithelial Gastrointestinal Tumors
- EUS-FNB vs. Single-incision Needle-knife (SINK) Biopsy for Gastrointestinal SELs
- EUS-guided Fine Needle Biopsy With a New Core Histology Needle Versus Conventional Fine Needle Aspiration
- Evaluate the Efficacy of AMG 706 to Treat Advanced Gastrointestinal Stromal Tumors
- Evaluation of a New EUS-guided Needle (ProCore) Comparing to EUS-TCB Needle (Quick-Core)
- Evaluation of Cognitive Function of Patients With Sunitinib or Sorafenib
- Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
- Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors
- Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GIST
- Expanded Access to Everolimus, for an Individual Patient With GIST (Gastrointestinal Stromal Tumors)(CTMS#18-0019)
- Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)
- Gastrointestinal Anastomosis Using MonoPlus® Suture
- Gastrointestinal Stromal Tumors (GIST) Registry
- Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST)
- Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI
- Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal Tumors
- Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery
- Imatinib Mesylate in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor
- Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor
- Imatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By Surgery
- Imatinib Mesylate in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumor
- Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor
- Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
- Imatinib Mesylate With or Without Surgery in Treating Patients With Metastatic Gastrointestinal Stromal Tumor That is Responding to Imatinib Mesylate
- Imatinib TDM in GIST
- Impact of the Inhibitors of Tyrosine Kinase on the Male Fertility
- Influence of an Acidic Beverage on the Imatinib Exposure After Major Gastrectomy
- Ipilimumab and Imatinib Mesylate in Advanced Cancer
- L-carnitine vs Placebo for the Treatment of Muscle Cramps After Imatinib in Gastrointestinal Stromal Tumors
- Laparoscopic Resection of Large Gastric Stromal Tumors
- Long Outcome of Endoscopic Submucosal Dissection for Small Gastrointestinal Stromal Tumors (
- Long Term Effects of Tyrosine Kinase Inhibitor Therapy on Ovarian Reserve and Fertility in Patients With Chronic Myeloid Leukemia or Gastrointestinal Stromal Tumor
- Long-term Surival of GIST Patients ≥ 10 Years on Imatinib
- Management of Imatinib-associated Severe Skin Rash in Patients With Gastrointestinal Stromal Tumor
- Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)
- Masitinib in Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST)
- Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib
- Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib
- Masitinib in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence
- MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
- MITIGATE-NeoBOM: A Study to Evaluate 68Ga- NeoBOMB1 in Patients With Advanced TKI-treated GIST Using PET/CT
- Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure
- Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor
- Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg
- Nilotinib in Advanced Gastrointestinal Stromal Tumors (GIST)
- Nilotinib Pharmacokinetics (PK) in Gastrointestinal Stromal Tumor (GIST): Nilotinib PK
- Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment
- NIR Fluorescence Imaging With ICG for the Intraoperative Identification of Gastrointestinal Stromal Cell Tumours
- Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery
- Non-Interventional Retrospective Correlation Of Tumor Mutational Status To Clinical Benefit Of GIST Patients Treated With Sunitinib
- Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery
- Observational Registry Data on GIST Patients
- Oncogenetic Panel and Integrated Clinical Data Registration Study for Wild Type Gastrointestinal Stromal Tumor Patients
- Open-label Trial of GlivecWith Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors
- Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib.
- Paclitaxel in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GIST) After Failure to Imatinib and Sunitinib
- Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib
- Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib
- Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)
- PDR001 Plus Imatinib for Metastatic or Unresectable GIST
- Perifosine + Sunitinib Malate for Patients With Advanced Cancers
- Perioperative Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor
- Permission to Collect Blood Over Time for Research
- Ph II CABOGIST in GIST
- Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma
- Ph II Study of Perifosine Plus Gleevec for Patients With GIST
- Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies
- Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST
- Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies
- Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)
- Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor
- Phase II Study of Regorafenib Continuous Dosing of Regorafenib in Patients With GISTs
- Phase ll Study of Imatinib Mesylate for the Neoadjuvant Treatment of Patients With Gastrointestinal Stromal Tumors (GIST)
- PLX9486 as a Single Agent and in Combination With PLX3397 or PLX9486 With Sunitinib in Patients With Advanced Solid Tumors
- Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutene
- Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST)
- Prediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Minimal Residual Disease Detected by Liquid Biopsy
- Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST
- Preventing Viral Pandemic Associated Risk of Cancer Death Using Less Invasive Diagnostic Tests- Liquid Biopsies
- Prospective Cohort Study of the Clinical Applications for the Pathologic Type, Staging, and Grading of GIST
- Prospective Database of Gastrointestinal Stromal Cell Tumors (GISTs)
- Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors
- Prospective Multicentric Randomized Study of Glivec® in Advanced GIST Expressing C-kit: Interruption After 5 Years vs Maintenance
- Prospective Trial of EUS-FNA Versus EUS-FNB Using a Novel Core Biopsy Needle
- Quick Skin Sealant in Closure of Surgical Wound After Laparoscopic Surgery
- Rechallenge of Imatinib in GIST Having no Effective Treatment: RIGHT
- Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]
- Regorafenib in GIST With Secondary C-KIT Exon 17 Mutation
- Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
- Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy
- Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program)
- Regorafenib Post-marketing Surveillance in Japan
- Ripretinib Combined With Surgery in Advanced GIST That Have Failed Imatinib Therapy: A Multicenter,Observational Study
- Ripretinib in Chinese Patients With Advanced GIST: a Real World Study
- Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)
- Ripretinib Used for Resectable Metastatic GIST After Failure of Imatinib Therapy
- Robotic Resection for Patients With Gastric Gastrointestinal Stromal Tumors: a Single-center Study
- Role of Surgery in Patients With Focally Progressive Gastrointestinal Stromal Tumors (GISTs) After Imatinib Treatment
- S9926 Temozolomide in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors
- Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors
- Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World
- Safety of Laparoscopic Resection for Gastrointestinal Stromal Tumor on Unfavorable Anatomic Site of Stomach
- Salvage Surgery for Patients With Metastatic GIST With Rego
- SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)
- Sarcopenia in Patients With Gastrointestinal Stromal Tumours
- Second-line Pharmacotherapy Patterns and Outcomes of Advanced Gastrointestinal Stromal Tumor: A Real-world Study
- Selinexor in Combination With Imatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors.
- Serum Dickkopf-4 as a Biomarker for the Diagnosis and Treatment of Gastrointestinal Stromal Tumor
- Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST
- Sorafenib for Imatinib/Sunitinib-failed GIST
- Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate
- Special Investigation For Gist Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan).
- SSG XXV: The Stop-GIST Trial; Discontinuation of Imatinib in Patients With Oligo-metastatic GIST
- Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib
- Study for Patients Previously Treated in Avapritinib Clinical Trials
- Study in Low Risk Gastrointestinal Stromal Tumor (GISTs)
- Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)
- Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients
- Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
- Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients
- Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)
- Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor
- Study of the Immunoresponse in Patients Treated With a Tyrosine Kinase Inhibitor
- Study of Tumor Samples in Patients Undergoing Treatment for Gastrointestinal Stromal Tumors on Clinical Trial ACOSOG-Z9001
- Study on the Influence of Sunitinib and Sorafenib on Fatigue, QoL, Depression in Patients With Metastatic RCC or GIST
- Study to Evaluate the Pharmacokinetic Characteristics of Luckyvec 400mg Tablet, in Healthy Subjects
- Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors
- SU5416 in Treating Patients With Advanced, Metastatic, or Recurrent Soft Tissue Sarcomas
- Surgery for Locally Unresectable Advanced GISTs Without Metastasis After Imatinib Therapy
- Surgery in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor
- Symptom Inventory for Gastrointestinal Stromal Tumors
- Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
- Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)
- Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)
- TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors
- The Effects of Preoperative and Postoperative Oral Nutritional Supplements in Malnourished Post-gastrectomy Patients
- The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib
- The Efficacy and Safety of Temozolomide in SDH-deficient GIST
- The GALLOP-11 Study
- The Oncopanel Pilot (TOP) Study
- To Compare the Efficacy of Surgery Followed by Sunitinib With Surgery Followed by Imatinib in GIST Patients With Progression on Imatinib.
- Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate
- Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib
- Treatment Patterns in Gastrointestinal Stromal Tumors in the Community Oncology Setting
- Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
- Unifying Advanced Treatment With Advanced Imaging
- Vaccine Therapy in Treating Patients With Metastatic Solid Tumors
- WB-DWI for Early Prediction of Therapy Response in Patients With Advanced Metastatic GIST Treated With Regorafenib
- A Modified (Retro-Tubercle) Opening Wedge High Tibial Osteotomy Versus the Conventional Technique
- Clinical Outcomes of Open Wedge High Tibial Osteotomy With Autologous Bone Marrow or Adipose-derived Stem Cell Therapy
- Effect of RO On GB During TKR Severe Varus Deformity
- Retrospective Evaluation of GGPSP’s Safety and Clinical Performance for the Treatment of Lower Limbs Deformities.
- RSA and Clinical Comparison of Anatomical and Mechanical Alignment in Total Knee Replacement